Definitive Healthcare Sees Q3 Adj EPS $0.04-$0.05 vs $0.04 Est; Sees Sales $54.000M-$55.000M vs $55.542M Est

Morgan Stanley Maintains Equal-Weight on Definitive Healthcare, Lowers Price Target to $1.5

Morgan Stanley analyst Craig Hettenbach maintains Definitive Healthcare (NASDAQ:DH) with a Equal-Weight and lowers the price target from $2.5 to $1.5.

Definitive Healthcare shares are trading higher after the company reported better-than-expected Q2 adjusted EPS results and raised its FY26 adjusted EPS guidance.

Definitive Healthcare Raises FY2026 Adj EPS Guidance from $0.16-$0.19 to $0.18-$0.20 vs $0.18 Est; Narrows FY2026 Sales Guidance from $220.000M-$226.000M to $220.000M-$222.000M vs $223.449M Est

Definitive Healthcare (NASDAQ:DH) raises FY2026 Adj EPS guidance from $0.16-$0.19 to $0.18-$0.20 vs $0.18 analyst estimate. Narrows FY2026 sales outlook from $220.000 million-$226.000 million to $220.000